Knockdown of S100P by lentiviral-mediated RNAi promotes apoptosis and suppresses the colony-formation ability of gastric cancer cells

Zhang,Qi; Hu,Haolin; Shi,Xin; Tang,Wenhao

doi:10.3892/or.2014.3104

Knockdown of S100P by lentiviral-mediated RNAi promotes apoptosis and suppresses the colony-formation ability of gastric cancer cells

Authors:
- Qi Zhang
- Haolin Hu
- Xin Shi
- Wenhao Tang
View Affiliations

Affiliations: Department of General Surgery, Zhongda Hospital, Southeast University, Gulou, Nanjing, Jiangsu 210009, P.R. China
Published online on: March 21, 2014 https://doi.org/10.3892/or.2014.3104
Pages: 2344-2350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

S100P is a putative candidate oncogene in several types of human tumors. However, expression of S100P, its potential role and its clinical significance in gastric cancer remain unclear. In the present study, S100P expression was examined by immunohistochemistry using a tissue microarray. Positive staining for S100P was noted in 77.1% of the cases while 22.9% were negative. In two gastric cancer cell lines, MGC-803 and SGC-7901, S100P expression was knocked down by a lentiviral short hairpin delivery system. The RNA interference-mediated downregulation of S100P expression markedly promoted cell apoptosis and inhibited cell colony-formation ability of the gastric cancer cells. In addition, knockdown of S100P significantly regulated the expression of 12 apoptosis-associated genes with a >1.5-fold change compared with the negative control. Among them, FOS, DDIT3 and FN1 were significantly upregulated, while FASLG, DAPK1, CTNNB1 and CASP2 were notably downregulated following S100P silencing. These results suggest that S100P acts as an oncogenic factor in gastric cancer and is a potential molecular target for gastric cancer gene therapy.

View Figures

View References

1	Garcia M, Jemal A, Ward EM, et al: Global Cancer facts & Figures 2007. American Cancer Society; Atlanta: 2007
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Sun XD, Mu R, Zhou YS, et al: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi. 26:4–9. 2004.(In Chinese).
4	Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 33:637–668. 2001. View Article : Google Scholar : PubMed/NCBI
5	Becker T, Gerke V, Kube E and Weber K: S100P, a novel Ca²⁺-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca²⁺-binding properties. Eur J Biochem. 207:541–547. 1992.
6	Arumugam T, Simeone DM, Golen KV and Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 11:5356–5364. 2005. View Article : Google Scholar : PubMed/NCBI
7	Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC and Huang EH: RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 50:1230–1240. 2007. View Article : Google Scholar : PubMed/NCBI
8	Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R and Rudland PS: Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 66:1199–1207. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE and Simm A: S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 43:1935–1943. 2007. View Article : Google Scholar : PubMed/NCBI
10	Austermann J, Nazmi AR, Muller-Tidow C and Gerke V: Characterization of the Ca²⁺-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem. 283:29331–29340. 2008.
11	Filipek A, Jastrzebska B, Nowotny M and Kuznicki J: CacyBP/SIP, a calcyclin and Siah-1-interacting p rotein, binds EF-hand proteins of the S100 family. J Biol Chem. 277:28848–28852. 2002. View Article : Google Scholar : PubMed/NCBI
12	Shyu RY, Huang SL and Jiang SY: Retinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells. J Biomed Sci. 10:313–319. 2003. View Article : Google Scholar : PubMed/NCBI
13	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
15	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
16	Parkkila S, Pan PW, Ward A, et al: The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol. 8:22008. View Article : Google Scholar : PubMed/NCBI
17	Ge F, Wang C, Wang W and Wu B: S100P predicts prognosis and drug resistance in gastric cancer. Int J Biol Markers. 28:e387–e392. 2013. View Article : Google Scholar : PubMed/NCBI
18	Jia SQ, Niu ZJ, Zhang LH, et al: Identifcation of prognosis-related proteins in advanced GC by mass spectrometry-based comparative proteomics. J Cancer Res Clin Oncol. 135:403–411. 2009. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Li X, Dong GL, et al: In silico analysis and verification of S100 gene expression in gastric cancer. BMC Cancer. 8:2612008. View Article : Google Scholar
20	Mátrai J, Chuah MK and VandenDriessche T: Recent advances in lentiviral vector development and applications. Mol Ther. 18:477–490. 2010.
21	Arumugam T, Simeone DM, Schmidt AM and Logsdon CD: S100P stimulates cell proliferation and survival via receptor for advanced glycation end products (RAGE). J Biol Chem. 279:5059–5065. 2004. View Article : Google Scholar : PubMed/NCBI
22	Basu GD, Azorsa DO, Kiefer JA, et al: Functional evidence implicating S100P in prostate cancer progression. Int J Cancer. 123:330–339. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kim JK, Jung KH, Noh JH, et al: Targeted disruption of S100P suppresses tumor cell growth by downregulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol. 35:1257–1264. 2009.PubMed/NCBI
24	Namba T, Homan T, Nishimura T, Mima S, Hoshino T and Mizushima T: Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects. J Biol Chem. 284:4158–4167. 2009. View Article : Google Scholar : PubMed/NCBI
25	Oyadomari S and Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11:381–389. 2004. View Article : Google Scholar : PubMed/NCBI
26	Dalton LE, Clarke HJ, Knight J, et al: The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer. 108:1340–1347. 2013. View Article : Google Scholar